TRIUMPH OLE

TYVASO showed sustained improvements in 6MWD1

TRIUMPH OLE Study Design: an OLE of the TRIUMPH study to evaluate the safety and dosing of TYVASO over time. Patients (N=206) from the placebo-controlled 12-week TRIUMPH study initiated TYVASO and entered the long-term, uncontrolled OLE study. NYHA FC II (11%), III (86%), IV (3%) at baseline.1,2

IMPROVEMENTS IN 6MWD OVER 18 MONTHS1

6MWD improvements over 18 months with TYVASO6MWD improvements over 18 months with TYVASO

Without a control group, data must be interpreted cautiously.

Patients who started TYVASO 12 weeks earlier had greater improvements in 6MWD.Patients who started TYVASO 12 weeks earlier had greater improvements in 6MWD.

LONG-TERM BENEFITS BEYOND 6MWD1,3

SUSTAINED IMPROVEMENTS IN NYHA FUNCTIONAL CLASS1

maintained or improved NYHA FC from baseline at 2 years (n=120)1,2

36% of patients had improvement in functional class from baseline at 6 months (n=174) and at 2 years (n=120)1,2

SURVIVAL EXCEEDED 80% AT 3 YEARS2

survival rate at 3 years (n=69)2

Based on a long-term follow-up of patients who were treated with TYVASO in the pivotal study and the OLE (Kaplan–Meier estimates of survival).2

These data are from an OLE study. Without a control group, data must be interpreted cautiously.

Safety from the OLE study2

  • AEs observed during this chronic dosing study were qualitatively similar to those observed in the 12-week placebo-controlled trial2
  • Serious AEs included pneumonia (n=15) and hemoptysis (n=3)2